Skip to content
‹ Back to IndustriesSciences

SpaceX Successfully Launches the Falcon Heavy Rocket

SpaceX launched Falcon Heavy on Feb. 6, sending a Tesla Roadster into orbit and landing two of three core boosters, a successful test run for future space exploration and travel.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from Spacex on MarketScale.

By Sciences · · Promoted Content
Share
SpaceX Successfully Launches the Falcon Heavy Rocket

Key takeaways

01

Elon Musk has made it his life mission to take humankind to space.

02

On February 6th, he got even closer to achieving that goal when his company SpaceX launched the historic maiden voyage of its Falcon Heavy Rocket, putting a Tesla Roadster into orbit, and landing two rocket boosters back on Earth.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Elon Musk has made it his life mission to take humankind to space. On February 6th, he got even closer to achieving that goal when his company SpaceX launched the historic maiden voyage of its Falcon Heavy Rocket, putting a Tesla Roadster into orbit, and landing two rocket boosters back on Earth. After a brief two-hour delay, the launch departed from Kennedy Space Center in Cape Canaveral, Florida—the same location from which NASA’s Apollo moon missions and space shuttles departed from.

The rocket itself is impressive. It stands at a massive 23 stories tall and is powered by 27 engines on three core boosters, which produces 5 million lbs. of thrust at liftoff. SpaceX, ever the innovator in composite applications, engineered the rocket’s payload fairing with a composite structure and carbon fiber face sheets that were manufactured in-house. It’s built to protect satellites during delivery to low-Earth orbit as well as geosynchronous transfer orbit.

That Tesla Roadster is something to see as well. Equipped with a mannequin named “Starman” after the 1972 David Bowie song, and a dashboard message of “Don’t Panic!” from the book Hitchhiker’s Guide to the Galaxy by Douglas Adams, the cherry red convertible is currently on a trajectory taking it past Mars, and on its way to orbit the sun. You can watch footage of it here.

After the success of the launch, two of the core boosters, designed to be reusable, returned to their designated areas in Cape Canaveral Air Force Station. The third was set to land on a landing pad in the Atlantic Ocean. It missed—taking out a drone ship nearby, and plunging into the water at 300 miles per hour. Despite this miscalculation, the test run was still a huge success for the future of space exploration and space travel.

“I think it’s going to open up a sense of possibility,” Musk was widely reported to have said after the launch. “We want a new space race. Space races are exciting.”

SpaceX is ready to lead the charge. With the success of the test run, the next steps include commercial satellite launches for the U.S. Air Force and a solar-sail mission for The Planetary Society. After that, SpaceX wants to send people to Mars as early as 2024.

“Crazy things can come true,” Musk added. “When I see a rocket lift off, I see a thousand things that could not work, and it’s amazing when they do.” Some of those amazing things working where they shouldn’t are undoubtedly because of the use of composites.

Magnum Venus Products is an innovator of composites, pumping and spraying equipment for closed/open molds, adhesives, and epoxies. MVP serves a multitude of manufacturers in a variety of industries such as automotive, aerospace, transportation, marine, railway, and oil & gas among many others. For more information on the great products MVP offers, visit the website!

Read more at mvpind.com

Spacex

Part of this channel

Spacex

Designing Rockets and Spacecraft for a Multiplanetary Future

Visit the channel

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz's AAV2 gene therapy for retinitis pigmentosa, through IND-enabling work and a planned Phase 1/2 trial. CLZ002 targets retinal repair, not mutations. Because the disease is linked to more than 90 genes, one manufacturing process could end up serving a broad patient group.

  • 01Retinitis pigmentosa has more than 90 causal genes; CLZ002 aims at a shared retinal repair pathway, so a single AAV2 manufacturing process would serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab hiring budgets for 2027 carry a net outlook of just +2, down from +10, while consumables sit at +30 and raw materials at +31. Labs are paying for supplies and planning capital purchases further ahead. New positions face the toughest scrutiny.

  • 01Labs heading into 2027 expect their reagent budgets to grow and their headcount budgets to stall: consumables carry a net outlook of +30, hiring just +2.
  • 02Lab Manager’s read: if consumables spending stays flat, the lab is probably buying less—because respondents reported rising costs across many supply items, from reagents to shipping.
  • 03Hiring gets treated as a recurring cost, not a one-time purchase; one published example estimates ~$46,000/year for a graduate student and $80,000–$100,000 for a postdoc (with fringe) at one institution. Lab Manager recommends justifying new roles with throughput, turnaround and risk—while separating price from volume in supply-line requests.

Nov 13, 2026

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra BioPharma Solutions opened Building H, a $250 million-plus addition to its Bloomington, Indiana campus, featuring two syringe lines and a vial line with lyophilizers. The CDMO plans to expand from 11 to 18 filling lines by 2027. Extra sites reduce supply risk only when products are qualified at both locations.

  • 01Simtra's network is set to grow from 11 to 18 filling lines across Indiana and Germany by 2027, a published capacity timeline sponsors can plan tech transfers against.
  • 02A second fill site cuts supply risk only after a product has been validated there; for biologics that means process validation, comparability work and regulatory filings first.
  • 03Programs whose real exposure sits in concentrated starting-material supply gain little from added fill-finish redundancy, however well the new lines are built.

Nov 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512